Advertisement
Screener

ACLARION, INC. (ACON) EBITDA

ACLARION, INC. (ACON) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$2.84M*; Operating income -$2.90M; Depreciation and amortization $61.87K*.
  • 2026-03-31: Basis Reported; EBITDA -$2.93M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$1.93M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$1.77M*; Operating income -$1.83M; Depreciation and amortization $58.36K*.

Complete source-backed ebitda history.

Available history
2023-03-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$2.84M*-$2.90M$61.87K*(m)(m)(m)-$2.66M*(m)$297.07K(m)$0.00
2026-03-31Reported-$2.93M(m)(m)(m)-13841.21%(m)-$2.64M(m)$315.42K(m)$0.00
2025-12-31Reported-$1.93M(m)(m)(m)-10453.38%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$1.77M*-$1.83M$58.36K*(m)(m)$7.32K*-$1.16M*(m)$302.04K(m)$0.00
2025-06-30Reported-$1.68M*-$1.74M$52.56K*(m)(m)(m)-$1.87M*(m)$270.43K(m)$0.00
2025-03-31Reported-$1.44M(m)(m)(m)-7565.47%(m)-$2.51M(m)$198.19K(m)$0.00
2024-12-31Reported-$1.75M(m)(m)(m)-17142.04%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$1.25M*-$1.30M$50.03K*(m)(m)$0.00*-$1.06M*(m)$195.80K(m)$0.00
2024-06-30Reported-$1.09M*-$1.14M$45.76K*(m)(m)(m)-$1.05M*(m)$202.10K(m)$0.00
2024-03-31Reported-$1.23M(m)(m)(m)-12163.32%(m)-$2.24M(m)$239.04K(m)$0.00
2023-12-31Reported-$1.08M(m)(m)(m)-7860.82%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$1.12M*-$1.16M$41.08K*(m)(m)(m)-$952.51K*(m)$198.25K(m)$0.00
2023-06-30Reported-$1.37M*-$1.41M$40.44K*(m)(m)(m)-$947.54K*(m)$250.01K(m)$0.00
2023-03-31Reported-$1.14M(m)(m)(m)-4483.30%(m)-$1.01M(m)$204.40K(m)$0.00
2022-09-30Reported(m)-$1.63M(m)(m)(m)(m)-$1.10M*(m)$290.97K(m)$0.00
2022-06-30Reported(m)-$2.21M(m)(m)(m)(m)-$2.41M*(m)$353.23K(m)$0.00
2022-03-31Reported(m)-$773.10K(m)(m)(m)(m)-$309.43K(m)$204.80K(m)$0.00
2021-09-30Reported(m)-$797.25K(m)(m)(m)(m)-$829.02K*(m)$275.28K(m)$0.00
2021-06-30Reported(m)-$626.62K(m)(m)(m)(m)-$492.20K*(m)$162.71K(m)$0.00
2021-03-31Reported(m)-$460.54K(m)(m)(m)(m)-$246.47K(m)$167.75K(m)$0.00

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$6.82M(m)(m)(m)-9012.26%$21.53K-$7.16M(m)$1.03M(m)$0.00
2024-12-31Reported-$5.32M(m)(m)(m)-11634.83%$5.12K-$5.27M(m)$888.77K(m)$0.00
2023-12-31Reported-$4.71M(m)(m)(m)-6250.74%$0.00-$3.65M(m)$873.34K(m)$0.00
2022-12-31Reported(m)-$5.56M(m)(m)(m)(m)-$4.95M(m)$1.07M(m)$0.00
2021-12-31Reported(m)-$2.95M(m)(m)(m)(m)-$2.40M(m)$787.85K(m)$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
Advanced Biomed Inc. (ADVB)$0.009B
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
BioNexus Gene Lab Corp (BGLC)$0.004B
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
Freenome, Inc. (FRNM)United States$0.143B
EXAGEN INC. (XGN)United States$0.212B-5.95
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45